including its ability to reach very high levels at intracellular spaces where Salmonella commonly resides despite its low serum levels and high MIC values have contributed to the good clinical response. However, an important concern is its prolonged sub-inhibitory concentrations at tissue might favour emergence of bacterial resistance highlighting the need to monitor MIC of Salmonellae against azithromycin. [1] Our results differ from other Indian reports of slightly higher azithromycin MICs while it is agreeable with data from other developing nations. [3, 4] In our study, S. Paratyphi-A seems to be relatively more resistant compared to S. Typhi, a fact that is supported by earlier report from Nepal that state the MICs of several antimicrobial agents were higher among isolates of S. Paratyphi-A. [5] Recently, increase in the occurrence of S. Paratyphi-A infections and non-availability of vaccine raises public health concern over this pathogen. Higher MICs Dear Editor, Increasing resistance to fluoroquinolone among Salmonellae has promoted the use of the third generation cephalosporins for treatment of enteric fever. Further, due to the availability of oral formulation, azithromycin has been a popular therapy for enteric fever in all age groups. [1] Until recently, no accepted breakpoints and disc diffusion zone interpretative criteria for azithromycin among Salmonellae were available although several clinical trials have stated good efficacy of azithromycin in treatment of enteric fever. [1] We present here the data on in-vitro activity of azithromycin on the clinical isolates of Salmonella Typhi and Salmonella Paratyphi-A based on updated breakpoints from a tertiary care hospital.
We tested 148 isolates of S. Typhi and S. Paratyphi-A for their susceptibility to ciprofloxacin and azithromycin by E-test (AB bioMérieux, Marcy l'Étoile, France) on BD Mueller-Hinton agar and results were interpreted, according to the new breakpoints established by Clinical and Laboratory Standards Institute. [2] Study isolates comprised of S. Typhi (95, 64%) and S. Paratyphi-A (53, 36%). The majority of isolates (97% S. Typhi and 98% S. Paratyphi-A) showed reduced susceptibility to ciprofloxacin. Resistance rates were higher among S. Paratyphi-A compared to S. Typhi (P < 0.001). All isolates were susceptible to azithromycin and similar to results of ciprofloxacin susceptibility, mean geometric minimum inhibitory concentration (MIC) was higher among S. Paratyphi-A as compared to S. Typhi. No multidrug-resistant (MDR) isolates were detected during the study period. All isolates were uniformly susceptible to ampicillin, ceftriaxone and trimethoprim/sulphamethoxazole and resistant to nalidixic acid by Kirby-Bauer disc diffusion method. Details of susceptibility are denoted in Table 1 . current guidelines on the treatment of enteric fever in India are limited due to varying rates of resistance across the country. While resistance to fluoroquinolones is steeply increased, reduction in MDR rates apparently encourages the use of old drugs in treatment of Salmonella infections. [3] Besides ceftriaxone, azithromycin is the recent addition to armamentarium against enteric fever. Lack of standards for in-vitro susceptibility tests did not deter the therapeutic use of azithromycin owing to its clinical success. Several pharmacological properties of azithromycin Azithromycin susceptibility among clinical isolates of Salmonella: Interfacing guidelines with routine practices of fluoroquinolones and azithromycin in the current study supports the upcoming resistance threat among S. Paratyphi-A.
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daptomycin may be a viable therapeutic option for VRE-UTI in Indian medical settings. Daptomycin is a concentration-dependent bactericidal agent, given in once daily dosage, [2] has fewer side effects, less drug interactions and no cross-resistance with other classes of antimicrobial agents. [3] Daptomycin was found to be active against 99.5% of Enterococcus faecium and 100% Enterococcus faecalis in surveys conducted on non-urinary enterococci across 27 medical centres of the United States in 2007-2008. [4] However, data on the daptomycin resistance in VRE causing UTI are scarce. This study was conducted in the Enteric Laboratory of the Department of Medical Microbiology, at PGIMER, Chandigarh, on 140 non-repetitive urinary isolates of enterococci recovered prospectively from hospitalised patients with UTI from January 2013 to June 2013. Strains were identified by conventional biochemical reactions; [5] screened for vancomycin, teicoplanin and daptomycin susceptibility by E-test (bioMérieux, New Delhi, India) and tested by Kirby-Bauer disc diffusion method for susceptibility to amoxicillin (10 μg), high level gentamicin (120 μg),
Dear Editor,
A global upsurge has been reported in the prevalence of vancomycin-resistant enterococcal urinary-tract infections (VRE-UTIs) with adverse clinical outcomes. [1] The proportion of nosocomial UTIs due to VRE increased 5-fold from 5.56% to 27.86% (P < 0.0001) in our institute as well (unpublished data). VRE are often resistant to multiple anti-microbial drugs such as ciprofloxacin, amoxicillin and gentamicin that are commonly used to treat UTI. Teicoplanin, linezolid, quinpristin-dalfopristin, etc., are optional compounds, usually reserved for the treatment of upper and/or bacteremic VRE-UTI; however, these agents have their own limitations. [1] Since usage of daptomycin, a lipopeptide antibiotic is rare in tertiary care centres. The reported cases of daptomycin non-susceptibility are expected to be low; and therefore,
Daptomycin: A viable therapeutic option for vancomycin-resistant enterococcal urinary-tract infections in Indian medical settings?
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